Copyright © 2021. Inderes Oyj. All rights reserved.

Remedy

Viimeisimmät raportit

Laaja raportti

Analyst

Atte Riikola

Atte Riikola

Analyytikko

Read more

Latest insider trading

Net impact profile

Tiedotteet
2.12.
2022

Redeye keeps its valuation range and base case unchanged despite a lowered revenue and EBIT expectation in 2023. Since decreased budget assumptions only have an impact on Remedy’s short-term revenue, we are still optimistic regarding its more long-term prospects, due to the fact that a lower budget in our view increases the royalty opportunity.

Read more and download the Research Update.

Third party research
2.12.
2022

Redeye keeps its valuation range and base case unchanged despite a lowered revenue and EBIT expectation in 2023.

Tiedotteet
28.11.
2022

Remedy Entertainment Plc | Stock Exchange Release November 28, 2022, at 4.00 p.m. (EET)

Remedy Entertainment Plc: Tencent Holdings Limited's shareholding in Remedy has gone above the 5 percent threshold

Remedy Entertainment Plc has on November 25, 2022, received a notification under Chapter 9, Section 5 of the Finnish Securities Markets Act according to which Tencent Holdings Limited's indirect shareholding of Remedy shares and voting rights has gone above the 5 percent threshold on November 25, 2022.

Tiedotteet
11.11.
2022

Remedy Entertainment Plc | Inside information November 11, 2022 at 2 p.m. (EET)

Remedy Entertainment signs a co-development and co-publishing agreement with 505 Games for Control 2

Remedy Entertainment ("Remedy") has signed an agreement with 505 Games, an international video game publisher and a subsidiary of Digital Bros Group, under which Remedy and 505 Games will co-develop and co-publish Control 2 (formerly known as Codename Heron), a sequel to Remedy's award-winning game Control.

Analyysi
31.10.
2022

Remedy's Q3 figures were softer than expected due to timing factors, but generally there was nothing surprising in the report. Remedy is now building the next growth leap of its strategy with the 5 major gaming projects under development.

Third party research
28.10.
2022

Revenues came in lower than expected during the quarter. However, Remedy communicated in its outlook that the company still expects its revenue to remain at the previous year’s level, which means a big chunk of revenue is expected in Q4.

Tiedotteet
28.10.
2022

Remedy Entertainment Plc | Stock Exchange Release October 28, 2022, at 9:00 a.m. (EEST)

Remedy Entertainment Plc | Business Review January-September 2022

Remedy's investments in game projects continued, burdening profitability

The next major game launch, Alan Wake 2, taking place as planned in 2023
 

The Business Review is unaudited. Figures in parentheses refer to the comparison period in the previous year unless otherwise stated.
 

Tiedotteet
28.10.
2022

Remedy Entertainment Plc | Stock Exchange Release October 28, 2022, at 8:45 a.m. (EEST)

Remedy Entertainment Plc's financial reporting and Annual General Meeting 2023

Remedy Entertainment Plc will publish its financial reports in 2023 as follows:
  • Financial statements release 2022 on Friday, February 10, 2023

  • Business review for January-March 2023 on Wednesday, April 26, 2023

  • Half-year financial report for January-June 2023 on Friday, August 11, 2023

Tiedotteet
3.10.
2022

Redeye lowers its expectations and valuation on Remedy. However, we expect a steady build-up period will be initiated at the beginning of 2023 when game projects move into the next phase of development. The Remedy stock is traded at half its value since our research update in April where we lowered our estimates and valuation. As in our initial coverage report in late 2018, we yet again state that Remedy offers investors “Premium at a discount”.

Third party research
3.10.
2022

Redeye lowers its expectations and valuation on Remedy. However, we expect a steady build-up period will be initiated at the beginning of 2023 when game projects move into the next phase of development.

Remedy

ipo